IN2014DN09963A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09963A
IN2014DN09963A IN9963DEN2014A IN2014DN09963A IN 2014DN09963 A IN2014DN09963 A IN 2014DN09963A IN 9963DEN2014 A IN9963DEN2014 A IN 9963DEN2014A IN 2014DN09963 A IN2014DN09963 A IN 2014DN09963A
Authority
IN
India
Prior art keywords
cancer
treatment
relates
soluble peptide
krfyvvmwkk
Prior art date
Application number
Other languages
English (en)
Inventor
Santos Susin
Pierre Launay
Philippe Karoyan
Hélène Merle-Beral
Original Assignee
Inst Nat Sante Rech Med
Université Pierre Et Marie Curie Upmc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Université Pierre Et Marie Curie Upmc filed Critical Inst Nat Sante Rech Med
Publication of IN2014DN09963A publication Critical patent/IN2014DN09963A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN9963DEN2014 2012-06-06 2013-06-06 IN2014DN09963A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305636 2012-06-06
PCT/EP2013/061727 WO2013182650A1 (en) 2012-06-06 2013-06-06 Method and pharmaceutical composition for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2014DN09963A true IN2014DN09963A (ja) 2015-08-14

Family

ID=48669879

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9963DEN2014 IN2014DN09963A (ja) 2012-06-06 2013-06-06

Country Status (6)

Country Link
US (4) US9198949B2 (ja)
EP (2) EP2858660B1 (ja)
JP (2) JP2015520178A (ja)
CN (1) CN104519898A (ja)
IN (1) IN2014DN09963A (ja)
WO (1) WO2013182650A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160183A1 (en) * 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
US11142548B2 (en) 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation
EP3454879B1 (en) * 2016-05-10 2021-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New compounds and pharmaceutical use thereof in the treatment of cancer
EP3243522A1 (en) * 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
CN107703109B (zh) * 2016-08-08 2021-01-15 华东理工大学 二维硫化钼多肽复合材料及其在靶向cd47癌症标记中的应用
EP3650036A1 (en) 2018-11-06 2020-05-13 Sorbonne Universite Synthetic peptides inducing immunogenic cell death

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5827498A (en) 1994-06-07 1998-10-27 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide
US5610271A (en) * 1995-06-07 1997-03-11 Torrey Pines Institute For Molecular Studies Kappa receptor selective opioid peptides
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
ATE317264T1 (de) * 1996-11-27 2006-02-15 Boston Heart Foundation Inc Neue low density lipoprotein bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US7223731B2 (en) * 2000-05-26 2007-05-29 Beth Israel Deaconess Medical Center, Inc. Thrombospondin-1 type 1 repeat polypeptides
WO2006089209A2 (en) * 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
JP2009013142A (ja) 2007-07-09 2009-01-22 Kyoto Univ 徐放用メソポーラスシリカ
JP5661988B2 (ja) 2008-02-26 2015-01-28 株式会社ペプタイドドア ムスカリンレセプター活性化剤及びペプチド

Also Published As

Publication number Publication date
JP2015520178A (ja) 2015-07-16
US20160039908A1 (en) 2016-02-11
EP2858660B1 (en) 2018-09-05
US20150126456A1 (en) 2015-05-07
US10759843B2 (en) 2020-09-01
JP2018057394A (ja) 2018-04-12
US20170362302A1 (en) 2017-12-21
EP3434276A1 (en) 2019-01-30
US9198949B2 (en) 2015-12-01
US20190135898A1 (en) 2019-05-09
WO2013182650A1 (en) 2013-12-12
EP2858660A1 (en) 2015-04-15
CN104519898A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014DN09963A (ja)
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
BR112014019901A8 (pt) Proteínas de fator viii recombinante
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
EA033399B1 (ru) Аналоги глюкагона с повышенной растворимостью и/или стабильностью и их применение
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
NZ708990A (en) Method for activating helper t cell
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
MX342171B (es) Peptido o complejo peptidico que se une a integrina ?2 y metodos y usos que implican a los mismos.
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
RU2015112625A (ru) Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
IN2014DN06920A (ja)
EA033437B9 (ru) Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний
NZ609474A (en) Fviii peptides for immune tolerance induction and immunodiagnostics